Literature DB >> 2511185

Tumor cells treated with vaccinia virus can activate the alternative pathway of mouse complement.

N Wakamiya1, N Okada, Y L Wang, T Ito, S Ueda, S Kato, H Okada.   

Abstract

Vaccinia virus has been shown to render mouse tumor cells highly immunogenic. Since we have demonstrated that induction of complement activating capacity on guinea pig tumor cells by Sendai virus infection causes the tumor cells to become immunogenic, we assumed that vaccinia virus infection of mouse tumor cells might render them reactive with homologous mouse complement. Therefore, murine tumor cells, MH134 and X5563, infected with vaccinia virus (VV) were incubated with mouse plasma and C3 deposition was determined by staining with fluorescein isothiocyanate-labeled anti-C3. We found that VV-infected tumor cells possess the ability to activate the alternative complement pathway (ACP) of murine complement. For induction of complement activating ability, at least a 3 h incubation of the infected MH134 cells was required indicating that the generation of ACP-activating capacity on MH134 infected with VV is time-dependent. Furthermore, ultraviolet-irradiated vaccinia virus was able to induce ACP-activating capacity on tumor cells as well.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2511185      PMCID: PMC5917831          DOI: 10.1111/j.1349-7006.1989.tb01712.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  21 in total

1.  The purification fo four strains of poxvirus.

Authors:  W K JOKLIK
Journal:  Virology       Date:  1962-09       Impact factor: 3.616

2.  Activation of the alternative pathway of guinea pig complement by Sendai virus-treated cells.

Authors:  N Okada; H Shibuta; H Okada
Journal:  Microbiol Immunol       Date:  1979       Impact factor: 1.955

3.  Species-specific inhibition by glycophorins of complement activation via the alternative pathway.

Authors:  H Okada; H Tanaka
Journal:  Mol Immunol       Date:  1983-11       Impact factor: 4.407

4.  Alteration of immunogenicity of xenogenized tumor cells in syngeneic rats by the immune responses to virus-associated antigens produced on immunizing cells.

Authors:  M Hosokawa; T Okayasu; K Ikeda; H Katoh; Y Suzuki; H Kobayashi
Journal:  Cancer Res       Date:  1983-05       Impact factor: 12.701

5.  Physicochemical characterization of a PMN-derived soluble fraction that enhances lymphocyte DNA synthesis.

Authors:  S Nakamura; F Goto; K Goto; M Yoshinaga
Journal:  J Immunol       Date:  1982-06       Impact factor: 5.422

6.  Prevention of complement activation on the homologous cell membrane of nucleated cells as well as erythrocytes.

Authors:  H Okada; H Tanaka; N Okada
Journal:  Eur J Immunol       Date:  1983-04       Impact factor: 5.532

7.  Feasibility of UV-inactivated vaccinia virus in the modification of tumor cells for augmentation of their immunogenicity.

Authors:  N Wakamiya; Y L Wang; H Imai; H X Gu; S Ueda; S Kato
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

8.  A new approach in specific, active immunotherapy.

Authors:  M K Wallack; Z Steplewski; H Koprowski; E Rosato; J George; B Hulihan; J Johnson
Journal:  Cancer       Date:  1977-02       Impact factor: 6.860

9.  Prevention of syngeneic tumor growth in vaccinia virus-primed mice by immunization with vaccinia virus-modulated tumor cells.

Authors:  K S Wu; S Ueda; Y Sakaue; Y Ohashi; K Ikuta; T Sugano; S Kato
Journal:  Biken J       Date:  1981-12

10.  Cytolysis of Sendai virus-infected guinea-pig cells by homologous complement.

Authors:  H Okada; H Tanaka; N Okada
Journal:  Immunology       Date:  1983-05       Impact factor: 7.397

View more
  2 in total

1.  Membrane-bound complement regulatory activity is decreased on vaccinia virus-infected cells.

Authors:  L Baranyi; N Okada; K Baranji; H Takizawa; H Okada
Journal:  Clin Exp Immunol       Date:  1994-10       Impact factor: 4.330

Review 2.  Poxvirus pathogenesis.

Authors:  R M Buller; G J Palumbo
Journal:  Microbiol Rev       Date:  1991-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.